Analyst Price Targets — URGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 10:45 am | Michael Schmidt | Guggenheim | $58.00 | $46.43 | TheFly | UroGen Pharma price target raised to $58 from $42 at Guggenheim |
| August 6, 2026 10:05 am | — | H.C. Wainwright | $75.00 | $46.43 | TheFly | UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright |
| July 21, 2026 12:01 pm | — | Guggenheim | $42.00 | $42.88 | TheFly | UroGen Pharma price target raised to $42 from $32 at Guggenheim |
| July 16, 2026 10:54 am | Leland Gershell | Oppenheimer | $50.00 | $39.80 | StreetInsider | UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer |
| July 15, 2026 9:14 pm | — | Goldman Sachs | $44.00 | $39.80 | TheFly | UroGen Pharma price target raised to $44 from $18 at Goldman Sachs |
| May 11, 2026 10:11 am | Raghuram Selvaraju | H.C. Wainwright | $45.00 | $29.40 | TheFly | UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright |
| April 9, 2026 8:21 pm | Amin Makarem | Jefferies | $40.00 | $20.53 | TheFly | UroGen Pharma initiated with a Buy at Jefferies |
| June 13, 2025 10:15 pm | Paul Choi | Goldman Sachs | $16.00 | $12.03 | TheFly | UroGen Pharma price target raised to $16 from $3 at Goldman Sachs |
| June 13, 2025 7:24 pm | Leland Gershell | Oppenheimer | $31.00 | $12.03 | TheFly | UroGen Pharma price target raised to $31 from $10 at Oppenheimer |
| October 14, 2024 7:13 am | Jason Kolbert | EF Hutton | $25.00 | $12.60 | StreetInsider | EF Hutton Starts UroGen Pharma (URGN) at Buy |
Latest News for URGN
PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
BlackRock Inc. purchased a new position in Urogen Pharma (NASDAQ: URGN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,201,461 shares of the company's stock, valued at approximately $117,814,000. BlackRock Inc. owned 6.57% of Urogen Pharma at the end of
The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel…
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for URGN.
U.S. House Trading
No House trades found for URGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.